Detection of mutations in the VP7 gene of vaccine-derived strains shed by monovalent rotavirus vaccine recipients

Mei Kaneko1, Sayaka Takanashi1,*, Mana Inoue1, Hiroshi Sakiyama2, Shoko Okitsu3, Masashi Mizuguchi1 and Hiroshi Ushijima3

Abstract

Strains of Rotarix, a live attenuated monovalent oral rotavirus vaccine, replicate in the intestine and are shed for about one month in immunocompetent recipients. The current study aimed to identify genetic changes of shed strains to reveal any significant mutations and their clinical impact on recipients. Stool samples of recipients of the first dose of Rotarix were sequentially collected for one month from the day of administration. Sequence analyses of the VP7 gene in eight recipients revealed five amino acid substitutions. Among them, two were observed in aa123, which is located in antigenic region 7-1a. Since there were no associated clinical symptoms, the genetic changes were unlikely to have caused reversion of pathogenicity of vaccine strain. Of interest, the virus in one case became closer to wild-type rotavirus via an amino acid change at aa123 occurring 14 days after administration, which might have resulted from multiple replications and long-term shedding of the vaccine strain.

INTRODUCTION

Rotavirus infection is a leading cause of acute gastroenteritis (AGE) among children under five years of age [1]. Rotaviruses contain 11 segments of double-stranded RNA encoding six structural proteins, VP1–VP4, VP6 and VP7, and six nonstructural proteins, NSP1–NSP5/6 (2). VP7, along with VP4, is an outer capsid neutralizing antigen, and is critical for genotyping of group A rotaviruses. Rotarix (GlaxoSmithKline, Rixensart, Belgium) is a live rotavirus monovalent vaccine, which is attenuated by multiple tissue culture passages of human G1P[8] parental strain [2]. Two doses are orally administered to infants at intervals of more than four weeks before six months of age. Although the vaccines are highly effective against severe rotavirus gastroenteritis [2], several concerns need to be mentioned. The first is shedding of vaccine strain. Shedding is detected as early as one day and as late as 28 days [3] with documented cases of horizontal transmission [4]. In immunocompromised infants, shedding is prolonged, for instance, for more than six months in infants with severe combined immune deficiency (SCID) [5]. The second concern is genetic alterations in the shed vaccine strains. A few studies reported detection of mutations in VP7, VP4, VP6 and NSP4 genes of those shed strains [6, 7]. However, the mutations were not analysed in detail. The position and frequency of the mutations, and their relevance to antigenicity of viruses remain to be clarified.

This study aimed to identify nucleotide mutations in vaccine strain sequentially shed after vaccination of the first dose of Rotarix to reveal any significant genetic changes and their clinical impact on recipients.

METHODS

Forty healthy infants vaccinated with the first dose of Rotarix at Sakiyama Pediatric Clinic in Tokyo were enrolled in the study from September 2014 to March 2015. Informed consent was obtained from guardians of all study participants. This study was approved by the ethical committee of the University of Tokyo under the registration number of 2014–10528.

Stool samples were collected sequentially from the day of vaccination (day 0) to day 14, followed by day 21 and day 28 with health condition record. Viral titres of shed Rotarix strains had been quantified by real-time reverse transcription (RT)-PCR essentially according to the method described by

Keywords: rotavirus; vaccine; shedding; VP7 gene; mutation.

Abbreviations: AGE, acute gastroenteritis; LB, Lysogeny broth; RT, reverse transcription; SCID, severe combined immune deficiency.
Gautam et al. [8]. Briefly, after RNA extraction by QIAamp Viral RNA mini kit (QIAGEN, Hilden, Germany), the viral titre was determined using TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Foster City, CA, USA), Rotarix-specific primers (NSP2-F and NSP2-R), and probe (NSP2-P) with a standard curve generated from serial dilutions of plasmid DNA carrying targeted region of Rotarix NSP2 (nt 592–872; 281 bp). The samples that met the following criteria were further analysed in this study: (i) samples from infants with four time points: one between day 1 and day 3, one between day 12 and day 14, one from day 21 and one from day 28; (ii) viral titre of Rotarix strain was more than 10^6 copies/g of stool; (iii) VP7 gene amplified fully. Samples from 29 infants met the criteria of (i) and samples from 11 infants further met the criteria of (ii). Samples from eight infants finally met the criteria of (iii). Consequently, 32 samples from eight infants were available for analysis in the current study.

Sanger sequencing for the VP7 gene was performed essentially according to the method described by Gouvea et al. [9] and Fujii et al. [10]. Briefly, after denaturation of extracted double-stranded rotavirus RNA with 50 % (v/v) dimethyl sulfoxide, RT reaction was performed with SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Synthesized cDNA was then used for PCR with PrimeSTAR GXL DNA polymerase (Takara, Shiga, Japan) with VP7 specific primers, Beg9 and End9. If the first attempt of amplification of VP7 gene failed, PCR incorporating inner primers Mid1r and Mid2 described by Trinh et al. [11] was performed to get overlapping fragments of the VP7 gene.

All PCR amplicons were purified with QIAquick PCR Puriﬁcation Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instruction. Purified amplicons were then sequenced using an ABI Prism BigDye termination cycle sequencing reaction kit (Applied Biosystems, Foster City, CA, USA). The sequence data was collected by an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). VP7 nucleotide alignments (nt 29–1035; 1007 bp without sequence of amplifying primers) were edited and analysed using mega6[12].

To confirm the important nucleotide mismatches between current samples and Rotarix original strain in antigenic region 7-1a, TA cloning was performed for a set of representative infants. Partial VP7 gene (nt 373–662; 290 bp) was cloned using TA Cloning Kit (Invitrogen, Carlsbad, CA, USA), pCR 2.1 vector (Invitrogen, Carlsbad, CA, USA) and Competent Escherichia coli DH5acells (Nippon Gene, Tokyo, Japan). In total, five white clones of each sample were picked up and incubated with vigorous shaking in liquid LB (Lysogeny broth) culture at 37°C overnight. Plasmid DNA was extracted using AxyPrep Plasmid Miniprep Kit (Funakoshi, Tokyo, Japan). The nucleotide sequences of the inserted PCR amplicons were determined by the universal M13-Forward primer.

RESULTS AND DISCUSSION

The age of eight infants and the details of each sample were described in Table 1. All the sequences were aligned with the VP7 gene of Rotarix original strain (accession no. JX943614). In total, ten nucleotide mutations were identified in six infants. Half of these mutations were nonsynonymous substitutions in amino acid at the position of aa 123, aa 134, aa 151 and aa 280 of the VP7 gene (Tables 2 and 3). The rate of mutation ranged from 0.00 to 0.21 %, and that of substitution from 0.00 to 0.63 %, respectively. Among five substitutions, two were found at the same position of aa 123, which belongs to antigenic region 7-1a as defined previously [13]. The substitutions at aa 123 were detected in two infants, no.9 and no.19. In infant no.9, both serine (S) and asparagine (N) were detected on day 3. In infant no.19, an amino acid substitution from S to N was detected since day 14 and it lasted until day 28.

TA cloning was carried out for the four samples from infant no.19 (samples of day 1, day 14, day 21 and day 28) to investigate the mutations and substitutions detected at aa 123. The TA cloning was also performed on the original

| Infant no. | Agea (week) | Day of sample collection and viral titre (log 10 copies/g of stool) |
|------------|-------------|------------------------------------------------------------------|
|            |             | Day (viral titre) | Day (viral titre) | Day (viral titre) | Day (viral titre) |
| 2          | 10          | 1 (7.81)          | 14 (7.72)          | 21 (6.90)          | 28 (6.72)          |
| 6          | 10          | 2 (9.08)          | 14 (9.89)          | 21 (9.94)          | 28 (6.77)          |
| 9          | 14          | 3 (9.31)          | 14 (9.88)          | 21 (9.90)          | 28 (9.43)          |
| 10         | 11          | 1 (7.62)          | 14 (8.14)          | 21 (7.08)          | 28 (7.68)          |
| 17         | 8           | 1 (8.70)          | 14 (9.30)          | 21 (7.43)          | 28 (8.21)          |
| 19         | 9           | 1 (8.13)          | 14 (7.93)          | 21 (9.08)          | 28 (8.86)          |
| 22         | 10          | 1 (8.58)          | 14 (8.88)          | 21 (7.50)          | 28 (7.70)          |
| 35         | 9           | 3 (8.88)          | 13 (8.79)          | 21 (8.20)          | 28 (7.97)          |

a. Age at vaccination of the first dose of Rotarix.
Rotarix solution (GlaxoSmithKline, Rixensart, Belgium; Lot: AROLB224AA) to confirm the existence of the nucleotides at aa 123, though it is deposited as S in GenBank with accession no. JX943614. Ratio of nucleotide (amino acid) at nt 416 (aa 123) in each sample was summarized in Table 4. Based on the results of TA cloning, the substitutions were observed from day 14 to day 28 as expected, with all the clones possessing N instead of S. Four out of five clones of the Rotarix original strain possessed S at aa 123 in accordance with the amino acid deposited in GenBank. Interestingly, one clone was found to possess N.

Ten nucleotide mutations and five amino acid substitutions in the VP7 gene of shed Rotarix strain were detected among vaccine recipients. The average rate of the mutations in the VP7 gene was 0.13 % within 28 days (Table 2). Based on this result, the evolutionary rate of the Rotarix VP7 gene was calculated as 1.00×10⁻⁴ nucleotide substitutions per site per

Table 2. Number and rate of mutations and substitutions detected among 32 samples from 8 infants

| Infant no. | Mutations of nucleotide | Substitutions of amino acid |
|------------|------------------------|----------------------------|
|            | Sequenced length (bp)  | Total no. of mutations     | Mutation rate (%) | Sequenced length (aa) | Total no. of substitutions | Substitution rate (%) |
| 2          | 957                    | 2                          | 0.21             | 319                    | 2                          | 0.63                  |
| 6          | 924                    | 0                          | 0.00             | 309                    | 0                          | 0.00                  |
| 9          | 981                    | 2                          | 0.20             | 326                    | 1                          | 0.31                  |
| 10         | 947                    | 2                          | 0.21             | 317                    | 1                          | 0.32                  |
| 17         | 933                    | 1                          | 0.11             | 311                    | 0                          | 0.00                  |
| 19         | 940                    | 2                          | 0.21             | 308                    | 1                          | 0.32                  |
| 22         | 990                    | 0                          | 0.00             | 326                    | 0                          | 0.00                  |
| 35         | 1001                   | 1                          | 0.10             | 326                    | 0                          | 0.00                  |
| Average    | 959                    | 1.25                        | 0.13             | 318                    | 0.63                       | 0.20                  |

a. Whole nucleotide length of the VP7 gene is 1062 bp.
b. Mutation rate was calculated as the total number of mutations/sequenced length (bp).
c. Whole amino acid length of the VP7 gene is 326 aa.
d. Substitution rate was calculated as the total number of substitutions/sequenced length (aa).

Table 3. Position and timing of the mutations and substitutions

| Infant no. | Mutations of nucleotide | Substitutions of amino acid |
|------------|------------------------|----------------------------|
|            | Position (nt) | Day1–3 | Day14 | Day21 | Day28 | Rotarix* | Position (aa) | Day1–3 | Day14 | Day21 | Day28 | Rotarix* |
| 2          | nt 499 | G     | G     | A     | G     | G       | aa 151 | D     | D     | D     | N     | D       |
|            | nt 887 | A     | A     | A     | G     | A       | aa 280 | Q     | Q     | Q     | R     | Q       |
| 9          | nt 321 | T / C | T     | T     | T     | T       | aa 91  | T     | T     | T     | T     | T       |
|            | nt 416 | G / A | G     | G     | G     | G       | aa 123 | S / N | S     | S     | S     | S       |
| 10         | nt 448 | T     | T     | T / C | T     | T       | aa 134 | Y     | Y     | Y     | Y / H | Y       |
|            | nt 834 | A     | A     | G     | A     | A       | aa 262 | Q     | Q     | Q     | Q     | Q       |
| 17         | nt 445 | T     | C     | C     | C     | C       | aa 133 | L     | L     | L     | L     | L       |
| 19         | nt 316 | G     | A     | A     | A     | A       | aa 90  | S     | S     | S     | S     | S       |
| 35         | nt 981 | C     | T     | T     | T     | C       | aa 311 | S     | S     | S     | S     | S       |

Nucleotides and amino acids covered by shadowing indicate mutations or substitutions compared with those of the Rotarix original strain.
a. Sequence of the VP7 gene of the Rotarix original strain was based on data deposited in GenBank (JX943614) [8].
b. Two peaks with the same height were identified in nucleotide sequences.
c. The definition of antigenic regions is based on the previous study [12].
Table 4. Ratio of nucleotide (amino acid) at nt 416 (aa 123) in each sample

| Nucleotide at nt 416 | Amino acid at aa 123 | Day 1 | Day 14 | Day 21 | Day 28 | Rotarix\(^a\) |
|---------------------|---------------------|-------|--------|--------|--------|-------------|
| G                   | Serine (S)          | 5     | 0      | 0      | 0      | 4           |
| A                   | Asparagine (N)      | 0     | 5      | 5      | 5      | 1           |
| Total no. of clones |                     | 5     | 5      | 5      | 5      | 5           |

\(^a\) Rotarix original solution (GlaxoSmithKine, Rixensart, Belgium; Lot:AROLB224AA) was used.

year (s/s/y). As proven, RNA viruses mutate quickly and hence evolve rapidly because of their error prone replications [14]. For several RNA viruses including rotaviruses, overall evolutionary rates range from $10^{-2}$ to $10^{-3}$ nucleotide s/s/y. In particular for rotaviruses, the evolutionary rate of the VP7 gene was $7.25 \times 10^{-4}$ nucleotide s/s/y [15]. Taken together, the evolutionary rate detected in this study was comparable to those reported in previous studies.

Based on the results of TA cloning, the strain of the original Rotarix solution was found to possess both S and N at aa 123, with predominance of S. The coexistence of two amino acids at the same position was likely due to quasispecies of RNA viruses [16]. Multiple cell passages for attenuation of the parental strain of Rotarix might be responsible for the mutations and quasispecies.

The aa 123 is located in antigenic region 7-1a that spans the intersubunit boundary [14, 17]. The genetic changes occur at another neutralizing antigen and enterotoxin respectively, analysed as well. In particular, VP4 and NSP4, which encode mutants on infants, the other remaining ten genes should be resulting in severe and persisting gastroenteritis. To clarify strains would be shed with a high titre and for a long period, from severe illnesses associated with vaccine strains. In Further investigations are necessary not only for healthy infants with severe combined immune deficiency. The authors declare that there are no conflicts of interest.

References
1. TateJE, BurtonAH, Boschi-PintoC, ParasharUD. World Health Organization–Coordinated Global Rotavirus Surveillance Network. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000–2013. Cln Infect Dis 2016;62:S96–S105.
2. TateJE, ParasharUD. Rotavirus vaccines in routine use. Cln Infect Dis 2014;59:1291–1301.
3. Hsieh Y-C, Wu F-T, Hsiung CA, Wu H-S, Chang KY et al. Comparison of virus shedding after live attenuated and pentavalent reassortant rotavirus vaccine. Vaccine 2014;32:1199–1204.
4. Riveral L, PeñaLM, StainierL, GillardP, CheuvartBet al. Horizontal transmission of a human rotavirus vaccine strain—a randomized, placebo-controlled study in twins. Vaccine2011;29:9508–9513.
5. Werther RL, Crawford NW, Boniface K, Kirkwood CD, Smart JM. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009;124:600.
6. Kaplon J, Cros G, Ambert-Balay K, Leruez-Ville M, Chomton M et al. Rotavirus vaccine virus shedding, viremia and clearance in infants with severe combined immune deficiency. Pediatr Infect Dis J 2015;34:326–328.
7. Klinkenberg D, Blohm M, Hoehne M, Mas Marques A, Malecki M et al. Risk of rotavirus vaccination for children with scid. Pediatr Infect Dis J 2015;34:114–115.
8. Gautam R, Esoda M, Mijatovic-Rustemapsic S, Ian Tam K, Gentsch JR et al. Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix(\(^a\)) and RotaTeq(\(^a\)) vaccine strains in stool samples. Hum Vaccin Immunother 2014;10:767–777.
9. Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990;28:276–282.

10. Fujii Y, Shimoike T, Takagi H, Murakami K, Todaka-Takai R et al. Amplification of all 11 RNA segments of group A rotaviruses based on reverse transcription polymerase chain reaction. Microbiol Immunol 2012;56:630–638.

11. Trinh QD, Nguyen TA, Phan TG, Khamrin P, Yan H et al. Sequence analysis of the VP7 gene of human rotavirus G1 isolated in Japan, China, Thailand, and Vietnam in the context of changing distribution of rotavirus G-types. J Med Virol 2007;79:1009–1016.

12. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596–1599.

13. Aoki ST, Settembre EC, Trask SD, Greenberg HB, Harrison SC et al. Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. Science 2009;324:1444–1447.

14. Jenkins GM, Rambaut A, Pybus OG, Holmes EC. Rates of molecular evolution in RNA viruses: a quantitative phylogenetic analysis. J Mol Evol 2002;54:156–165.

15. Nagaoka Y, Tatsumi M, Tsugawa T, Yoto Y, Tsutsumi H. Phylogenetic and computational structural analysis of VP7 gene of group A human rotavirus G1P[8] strains obtained in Sapporo, Japan from 1987 to 2000. J Med Virol 2012;84:832–838.

16. Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev 2012;76:159–216.

17. Zeller M, Patton JT, Heylen E, De Coster S, Ciarlet M et al. Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq. J Clin Microbiol 2012;50:966–976.

18. Mouna BHF, Hamida-Rebai MB, Heylen E, Zeller M, Moussa A et al. Sequence and phylogenetic analyses of human rotavirus strains: comparison of VP7 and VP8(∗) antigenic epitopes between Tunisian and vaccine strains before national rotavirus vaccine introduction. Infect Genet Evol 2013;18:132–144.

19. Estes MK, Greenberg HB. Rotaviruses. In: FieldsBN, KnipeDM, HowleyPM (editors). Fields Virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.